GlassScriptPhysician profile
Ralphana L Ehrhardt
NPI 1104829910
$4,266.03
in general payments reported to CMS, 2019-2025
18 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $247 · 2021: $427 · 2022: $1,156 · 2023: $778 · 2024: $846 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.04 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $644.38 | 2019-2024 | Cequa |
| Alcon Vision LLC | $394.83 | 2020-2025 | Rocklatan |
| Glaukos Corporation | $393.70 | 2019-2025 | Idose, Idosetr, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Aerie Pharmaceuticals, INC. | $376.79 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $373.05 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Biotissue Holdings INC. | $340.31 | 2022-2025 | |
| Allergan, INC. | $310.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $182.71 | 2019-2023 | |
| Rxsight INC | $133.37 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.03 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $54.65 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $34.57 | 2019-2021 | |
| Dompe US, INC. | $21.24 | 2025 | Oxervate |
| Thea Pharma INC. | $18.54 | 2024 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $18.39 | 2019 | |
| Harrow Eye, LLC | $15.86 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $15.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralphana Ehrhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.